Article Per Year (5 Year)
p-Index From 2021 - 2026
0.23
P-Index
This Author published in this journals
All Journal INDONESIAN JOURNAL OF BIOMEDICAL SCIENCES Zuriat JURNAL ITENAS REKAYASA REKA GEOMATIKA Avatara CERMIN PERMANA UNEJ e-Proceeding InfoTekJar : Jurnal Nasional Informatika dan Teknologi Jaringan MNJ (Malang Neurology Journal) BIOMA Jurnal Ilmiah Pendidikan dan Pembelajaran Pharmaceutical Journal of Indonesia Hubungan Tingkat Pengetahuan Petugas Pengelola Obat dengan Tingkat Ketersediaan Obat Di Puskesmas Kota Malang Jurnal Ilmiah Sultan Agung
SUMARNO
Universitas Negeri Yogyakarta
Religion Agriculture, Biological Sciences & Forestry Arts Humanities Biochemistry, Genetics & Molecular Biology Civil Engineering, Building, Construction & Architecture Computer Science & IT Earth & Planetary Sciences Economics, Econometrics & Finance Education Electrical & Electronics Engineering Health Professions Immunology & microbiology Law, Crime, Criminology & Criminal Justice Medicine & Pharmacology Neuroscience Nursing Public Health

Published : 45 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

 1 
ALIROCUMAB : MECHANISM OF ACTION, PHARMACOKINETICS, SAFETY, AND CLINICAL OUTCOMES Medina, Farah; -, Sumarno
Pharmaceutical Journal of Indonesia Vol 5, No 1 (2019)
Publisher : Brawijaya University

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Hyperlipidemia is an established risk factor for developing cardiovascular disease (CVD). The latest guideline on lipid management emphasize treatment with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) at doses proven to reduce CVD events.  However, some of statin-treated patients have persistently elevated cardiovascular risk due to inadequate lowering of low density lipoprotein cholesterol (LDL-C) levels. In addition, adverse effects of statins may limit their tolerability and therefore the ability to attain effective doses in some patients. A new class of drugs that inhibit proprotein convertase subtilisin-kexin type 9 (PCSK9) has been developed to treat hyperlipidemia.  PCSK9 inhibitors are monoclonal antibodies for proprotein convertase-subtilicin/kexin type 9 which significantly reduces the concentration of LDL-C in vivo by inhibiting the degradation of LDL receptors in hepatocytes. The introduction of the PCSK9 inhibitor was heralded a new era of intensive LDL-C reductions with LDL-C concentrations lowered below the rate that once thought possible with conventional treatments such as statins. On July 24, 2015, the United States Food and Drug Administration (FDA) approved Alirocumab, the first converged proprotein of the Subtilisin Kexin 9 (PCSK9) inhibitor. This review discusses the mechanisms of action, pharmacokinetics, safety and clinical outcomes of the Alirocumab.
Co-Authors , SUFIATIN - Indrianawati AGUSTRI AYU, WULAN AHMAD AZHAR, EMIR AROFIAH, NANDA AYU MAGFIROH, DIAH BAGUS ROHMAN PRADIPTA, ADITYA Cahyono, Erwin Budi Eka, Ervina Eka, Ervina EKO SUBAGTIO, MUHAMMAD Ernawati, Iin GAGAH PRAMA WIBAWA, MAS Gunistiyo, Gunistiyo Hanik Badriyah Hidayati,* Mohammad Hasan Machfoed,* Kuntoro,** Soetojo,*** Budi Santoso,**** Suroto,***** Budi Utomo****** Herlina Herlina I Dewa Made Sukrama I NYOMAN MANTIK ASTAWA I Wayan Sudhana IVAN NUR YASIN, MOH. Iwang Yusuf JANNAH, MIFTAKUL K. Sukardika Ketut Suwitra MAULIDINA, HIDAYAH Medina, Farah Mulyanto . MUSTIFARIS NUGROHO, AGUNG Nahara Amari, Syarifa Nahara Amari, Syarifa NAHDIA, IMROATUN Nani Zuraida NUR PUTRIATI, TRI Prasetiyo . Purwo Subekti PUTRI DANA ISWARA, LARAS RAMADHANI, SALSABILA Ramadhani, Syifa Eka RAVANA PUTRI, RISKA SAPUTRI, DIAN SETIAWAN, HANIF shamsu, nur SURYA ARIFIAN, DWI